Bayer Set To Sew Up HCC Market As RESORCE Hits Endpoint
Top-line success for Bayer's trial of Stivarga in advanced liver cancer in patients who have progressed on its other therapy Nexavar gives the company an opportunity to dominate the market, but Stivarga's potential may be overshadowed by its drawbacks and looming competition.